Starlab Space Announces Partnership with Helogen to Advance Life Sciences Research in Microgravity
MWN-AI** Summary
Starlab Space LLC has announced a significant partnership with Helogen Corporation aimed at revolutionizing life sciences research in microgravity. The collaboration focuses on integrating Helogen's HEL-IOS™ orbital biomedical operating system into the Starlab space station, which will enable continuous and autonomous biological discovery in low Earth orbit (LEO). This advancement moves research from isolated experiments to persistent, scalable operations, marking a transformative step in space-based scientific inquiry.
HEL-IOS™ is designed for fully autonomous regulatory-grade manufacturing of high-value biomaterials, incorporating biological cultivation, processing, sequencing, and analytics into a single closed-loop system. By embedding this automation directly into Starlab’s infrastructure, the station can evolve from a mere laboratory to an industrial production facility, enhancing the research capabilities available to scientists and commercial partners.
This partnership promises to decrease operational overhead and the need for frequent flights, facilitating a continuous workflow that accelerates scientific discovery. According to Helogen CEO Shishir Bankapur, microgravity offers a unique environment that may unlock biological processes that gravity hinders, allowing for advancements in medicine and material science. Starlab CEO Marshall Smith echoed these sentiments, emphasizing that the integration of HEL-IOS™ positions researchers to conduct ongoing discovery instead of transient experiments.
The collaboration builds on Starlab’s commitment to biopharmaceutical research in orbit, leveraging microgravity to enhance protein crystallization for drug development and 3D cell growth, among other applications. As part of a joint venture involving established corporations and entities, Starlab aims to ensure a seamless transition in microgravity research following the retirement of the International Space Station, expanding opportunities for commercial science and technological progress in space.
MWN-AI** Analysis
The recent announcement of Starlab Space's partnership with Helogen Corporation marks a pivotal moment in the commercialization of low Earth orbit (LEO) research, particularly in the life sciences sector. The integration of Helogen’s HEL-IOS™ orbital biomedical operating system into the Starlab platform will enhance the efficiency and scalability of biomedical research in microgravity, transforming it into a robust manufacturing ecosystem.
Investors should consider several implications of this partnership. Firstly, the ability to conduct continuous, autonomous biological discovery in space mitigates operational complexities. Researchers can expect accelerated timelines for experimentation and discovery, which offers substantial commercial viability stemming from high-value biomaterials. This innovation supports significant advancements in pharmaceuticals and regenerative medicine, areas poised for substantial growth.
Secondly, the shift from isolated experiments to persistent discovery platforms in orbit positions Starlab as a leader in the emerging space economy. As a joint venture involving prominent entities like Voyager Technologies and Airbus, this partnership enhances the credibility and potential market penetration of Starlab's offerings. The capability to reduce operational costs through automated processes could appeal to a diverse range of investors interested in space-based biomanufacturing—an industry that could see exponential growth over the next decade.
Moreover, Starlab’s model of offering user-driven, rapidly deployable capabilities on a commercial scale provides a competitive advantage. The seamless transition from the International Space Station to Starlab will likely attract ongoing investment and research opportunities, further solidifying its place in the market.
In summary, the collaboration between Starlab and Helogen offers a compelling investment opportunity, particularly as the global demand for innovative biomedical solutions continues to rise. This strategic integration not only enhances operational efficiency but also establishes Starlab as a frontrunner in the evolving landscape of space research and manufacturing. Investors should closely monitor developments in this sector for opportunities related to both companies and their significant market potential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
The Helogen HEL-IOS™ orbital biomedical operating system will be integrated in the Starlab space station to enable continuous, autonomous biological discovery in low Earth orbit.
Starlab Space LLC , the commercial space station developer expanding access to low Earth orbit research, today announced a partnership with Helogen Corporation , the automation platform industrializing orbit by enabling scalable, regulatory-grade manufacturing and autonomous biological operations in space. Together, the companies will expand how life sciences research is conducted in microgravity, moving from isolated experiments toward persistent, scalable discovery in orbit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218414892/en/
HEL-IOS™ enables fully autonomous, regulatory-grade manufacturing of high-value biomaterials in orbit by integrating biological cultivation, processing, sequencing and in-line analytics into a single closed-loop system that operates without continuous crew intervention. By embedding end-to-end automation directly into the station infrastructure, HEL-IOS™ will transform Starlab from a strictly lab environment into a scalable production facility.
Through the partnership, Helogen will integrate HEL-IOS™, the world’s first orbital biomedical operating system, into the Starlab ecosystem. HEL-IOS™ enables fully autonomous regulatory-grade manufacturing of high-value biomaterials in orbit by integrating biological cultivation, processing, sequencing and in-line analytics into a single closed-loop system that operates without continuous crew intervention. By embedding end-to-end automation directly into station infrastructure, HEL-IOS™ transforms orbital platforms from experimental environments into scalable production facilities. Commercial partners can scale industrial output with fewer flights and reduced operational overhead, while researchers gain continuous, automated workflows that accelerate discovery without dependence on crew-tended operations or frequent sample return. The result is a persistent manufacturing capability in orbit, positioning Starlab as an industrial node in the emerging space economy rather than a destination for isolated missions.
“Microgravity is not just a research environment. It’s a fundamentally new manufacturing and discovery regime,” said Shishir Bankapur, CEO of Helogen. “At Helogen, our mission is to unlock biological processes that Earth’s gravity suppresses and translate them into scalable breakthroughs in medicine and materials. Starlab’s globally accessible orbital platform, combined with HEL-IOS™, allows researchers to run, iterate and scale biology in space faster than ever before, shifting from one-off experiments to continuous, high-throughput discovery.”
“This partnership reflects exactly how we envision life sciences operating in low Earth orbit,” said Marshall Smith, CEO of Starlab. “By integrating autonomous biological systems like HEL-IOS™ into Starlab, we’re enabling researchers to move beyond short-duration experiments and toward sustained discovery and manufacturing workflows that can deliver real impact on Earth.”
The announcement builds on Starlab’s growing capabilities in biopharmaceutical and life sciences research in orbit. Microgravity offers conditions that cannot be replicated on Earth, allowing for improved protein crystallization to support drug development, 3D cell growth and disease models that more closely mimic human biology, and advanced stem cell research with potential applications for treating conditions such as Parkinson’s disease, diabetes and Alzheimer’s.
Starlab’s market-driven business model is designed to reduce cost, complexity and risk for researchers and commercial partners. Its single-launch, no-assembly-required architecture enables full certification and operational readiness within weeks from launch, minimizing delays and maximizing efficiency for payload customers. Through its joint venture partners, customers can conduct research aboard the International Space Station today, ensuring a seamless transition to Starlab as its next-generation capabilities come online.
About Starlab
Starlab Space is a U.S.-led, global joint venture among Voyager Technologies (NYSE: VOYG), Airbus , Mitsubishi Corporation , MDA Space , Palantir Technologies and Space Applications Services , with strategic partners including Hilton, Journey, Northrop Grumman and The Ohio State University. Starlab is developing a next-generation, AI-enabled commercial space station, aiming to ensure continued human presence in low-Earth orbit and a seamless transition of microgravity science and research alongside the retirement of the International Space Station. Starlab's advanced, user-driven design and robust capabilities make it a premier platform for scientific discovery and technological advancement in space. For more information, visit starlab-space.com .
About Helogen
Helogen is an American orbital industrial automation platform. The company is industrializing space by enabling scalable, regulatory-grade manufacturing of high-value biomaterials that achieve performance advantages over terrestrial production.
Helogen deploys autonomous orbital automation systems powered by its proprietary operating system, HEL-IOS™, integrating biological cultivation, processing, and real-time analytics into a continuous in-space workflow. This infrastructure supports industrial-scale biomaterial production while allowing researchers to run end-to-end automated experiments in orbit with fewer flights and minimal crew intervention.
By embedding persistent automation into next-generation space infrastructure, Helogen transforms orbital platforms into scalable industrial facilities that accelerate both commercial manufacturing and breakthrough discovery. For more information, visit www.helogen.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260218414892/en/
MEDIA CONTACT:
Starlab Space
Melissa Price, melissaprice@griffincg.com
Helogen Corporation
Janelle Classen, janelle.classen@helogen.com
FAQ**
How will the integration of Helogen's HEL-IOS™ with Starlab's operations affect the potential investment outlook for Voyager Technologies Inc. Class A VOYG in the commercial space sector?
What are the expected financial implications for Starlab Space LLC and its partners, including Voyager Technologies Inc. Class A VOYG, due to the automation capabilities offered by HEL-IOS™?
In what ways could the advancements provided by HEL-IOS™ change the competitive landscape for companies like Voyager Technologies Inc. Class A VOYG operating in low Earth orbit research?
How might the commercialization of high-value biomaterials through HEL-IOS™ influence the growth trajectory of Voyager Technologies Inc. Class A VOYG in the burgeoning space economy?
**MWN-AI FAQ is based on asking OpenAI questions about Voyager Technologies Inc. Class A (NYSE: VOYG).
NASDAQ: VOYG
VOYG Trading
6.34% G/L:
$36.21 Last:
1,371,870 Volume:
$36.20 Open:
